Biology

Lovelace’s Novel Nucleoside LCMS Assay to Be Presented at 12th Workshop on Regulations in Bioanalysis

Increasingly, biopharmaceutical companies are developing nucleoside analogues as chemotherapeutic, anti-bacterial and anti-viral agents.

Of the nucleoside analogues in development, 5-azacytidine is being studied as a targeted therapy for lung cancer, as it may be able to amplify the therapeutic agent at the site of action while reducing off-site toxicities.

The post Lovelace’s Novel Nucleoside LCMS Assay to Be Presented at 12th Workshop on Regulations in Bioanalysis appeared first on Lovelace Biomedical.

Source link

Related posts

ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2019 Cohort of Life Science Startups

Newsemia

Early-career researchers: an interview with Sharlene Santana [CONVERSATION]

Newsemia

H2A.Z facilitates licensing and activation of early replication origins

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World